Table 2.

Reasons for treatment changes according to each individual DMT

	Alemtuzumab	Dimethylfumarate	Fingolimod	Glatiramer	Interferons	Natalizumab	Rituximab	Teriflunomide
	Treatment switch ( N  = 404)
Total	3	7	79	22	219	47	4	23
Disease activity n (%)	3 (100)	3 (42.9)	62 (77.2)	9 (40.1)	116 (52.9)	11 (23.4)	2 (50.0)	14 (60.8)
Safety n (%)	0 (0.0)	2 (28.6)	11 (13.9)	4 (18.2)	69 (31.5)	4 (8.5)	1 (25.0)	6 (26.1)
Reproductive issues n (%)	0 (0.0)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Administrative issues n (%)	0 (0.0)	0 (0.0)	0 (0.0)	2 (9.5)	6 (2.8)	1 (2.1)	0 (0.0)	0 (0.0)
JC virus n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	33 (70.2)	0 (0.0)	0 (0.0)
Other n (%)	0 (0.0)	0 (0.0)	3 (3.8)	2 (9.5)	7 (3.2)	1 (2.1)	1 (25.0)	1 (4.3)
Unknown n (%)	0 (0.0)	2 (28.6)	3 (3.8)	4 (18.2)	33 (15.1)	2 (4.3)	0 (0.0)	2 (8.7)
	Treatment suspension ( N  = 186)
Total	2	5	21	11	106	24	9	8
Disease activity n (%)	0 (0.0)	0 (0.0)	1 (4.8)	0 (0.0)	15 (14.2)	1 (4.2)	2 (25.0)	0 (0.0)
Safety n (%)	0 (0.0)	2 (40.0)	3 (14.3)	2 (18.2)	27 (25.5)	0 (0.0)	1 (12.5)	1 (12.5)
Reproductive issues n (%)	0 (0.0)	1 (20.0)	6 (28.6)	4 (36.4)	17 (16.0)	4 (16.7)	0 (0.0)	2 (25.0)
Administrative issues n (%)	0 (0.0)	2 (40.0)	9 (42.9)	2 (18.2)	13 (12.3)	9 (37.5)	4 (50.0)	4 (50.0)
JC virus n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11 (45.8)	0 (0.0)	0 (0.0)
Other n (%)	2 (100.0)	0 (0.0)	1 (4.8)	2 (18.2)	14 (13.2)	1 (4.2)	0 (0.0)	1 (12.5)
Unknown n (%)	0 (0.0)	0 (0.0)	2 (9.5)	2 (18.2)	27 (25.5)	2 (8.3)	1 (12.5)	1 (12.5)